Document:

Employment Agreement with William J. Sasiela

 Exhibit 10.6 
 EMPLOYMENT AGREEMENT 
 This EMPLOYMENT AGREEMENT (this “Agreement”) is dated
as of the 1st day of December 2005, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and William J. Sasiela (the “Executive”). 
 WITNESSETH: 
 The Company desires to
employ the Executive, and the Executive wishes to accept such employment with the Company, upon the terms and conditions set forth in this Agreement. 
 In consideration of the mutual promises and agreements set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be
legally bound, agree as follows: 
 1. Employment. The Company hereby employs the Executive as Chief Medical Officer and Vice
President Clinical Development, and the Executive hereby accepts such employment by the Company upon the terms and conditions hereinafter set forth. 
 2. Employment Period. Subject to the provisions of Section 7 hereof, the term of this Agreement shall be for an initial period of four (4) years from the Effective Date, and may be renewed for
an additional period to be mutually determined by the parties hereto on the same terms an conditions as set forth herein. The term of the Executive’s employment hereunder, including any continuation of the original term, is hereinafter referred
to as the “Employment Period.” 
 3. Compensation. For performance of all services rendered under this Agreement, the
Company shall pay the Executive a base salary at annual rate of $225,000 in installments payable in accordance with the Company’s customary payroll practices but no less frequently than once each month. The Company shall withhold from any and
all payments required to be made to the Executive pursuant to this Agreement all federal, state, local and/or other taxes that are required to be withheld in accordance with applicable statutes and/or regulations from time to time. As a part of the
restricted stock grant you will also be entitled to receive a one-time cash payment of $10,000, such amount to be paid on or before April 15, 2006 and subject to your being still an employee of the Company at the time of the payment. The
Executive shall also be eligible for a merit bonus in such amount and payable at such time or times as the Board of Directors of the Company (the “Board”) may in its sole discretion determine. The Executive has a target bonus
opportunity of twenty-five percent (25%) of the base salary, assuming achievement of a series of mutually agreed upon performance milestones set each fiscal year. The actual amount, if any, shall be determined by the Board in its sole
discretion. The Executive shall receive a performance review on an annual basis, which will include a determination of potential adjustment of the Executive’s base salary, along with an assessment of the aforementioned merit bonus. The Board
may also consider on an annual basis, a grant of stock 

 
incentives, including but not limited to incentive stock options, pursuant to the Company’s stock incentive plan, in recognition of the Executive’s
performance for the preceding year. Nothing herein should be interpreted as a guarantee of a salary increase, merit bonus, or grant of stock incentives. The Company shall use commercially reasonable efforts to pay any cash bonuses that the Executive
receives by April 1st of the following year. 
 4. Duties. The Executive shall be employed as an executive of the Company, and
shall have such executive level duties as are assigned or delegated to him by the Board or its designee. The Executive shall devote his entire working time, attention and energy exclusively to the business of the Company and shall cooperate fully
with the Board in the advancement of the best interests of the Company. The Executive agrees not to engage in any activities outside of the scope of the Executive’s employment that would detract from, or interfere with, the fulfillment of his
responsibilities or duties under this Agreement. The Executive agrees that the Executive will not serve as a director or the equivalent position of any company or entity, except for not-for-profit entities, and will not render services of a
business, professional or commercial nature to any other person or firm, except for not-for-profit entities without the prior written consent of the Board, which consent shall not be unreasonably withheld. If elected as a director of the Company,
the Executive agrees to fulfill the duties of such offices without additional compensation. 
 5. Expenses. Subject to compliance by
the Executive with such policies regarding expenses and expense reimbursement as may be adopted from time to time by the Company, the Executive is authorized to incur reasonable expenses in the performance of his duties hereunder in furtherance of
the business and affairs of the Company, and the Company will reimburse the Executive for all such reasonable expenses, upon the presentation by the Executive of an itemized account satisfactory to the Company in substantiation of such expenses when
claiming reimbursement. 
 6. Employee Benefits; Vacations. The Executive shall be eligible to participate in such life insurance,
medical and other employee benefit plans of the Company that may be in effect from time to time, to the extent he is eligible under the terms of those plans, on the same basis as other similarly-situated executive officers of the Company. The
Company may from time to time modify or eliminate any or all benefits extended or provided in its sole discretion. The Executive shall be entitled to paid vacations in accordance with the policies of the Company in effect from time to time, as
determined by the Board. 
 7. Termination. Upon termination of the Executive’s employment, the Executive will be entitled to any
earned but unpaid base salary and bonus as well as the following additional benefits: 
 (a) In the event that the
Executive’s employment is terminated by the Company for reasons other than Cause (as such term is defined in Section 11 below) or in the event the Executive resigns his employment for Good Reason (as defined in
Section 11 below), the Executive will be provided a severance package with continuation of full salary and benefits and, at the discretion of the Board, prorated bonus to the target level. Such severance package will be paid for a period
of nine (9) months from the date of termination. The Executive’s severance will be subject to set off in the event that the Executive obtains other employment during such severance period. 
  

 2 

 (b) In the event that the Executive’s employment is terminated for Cause or the
Executive resigns without Good Reason, the Executive will not be entitled to a severance package. 
 (c) In the event that the
Executive’s employment is terminated by reason of his death or Disability (as such term is defined in Section 11 below) the Executive or his estate will be provided a severance package with continuation of salary and benefits and,
at the discretion of the Board, prorated bonus to the target level. Such severance package will be paid for a period of six (6) months from the date of termination. 
 (d) Pursuant to tax regulations, with respect to any incentive stock options the Executive may be granted, in the event that the
Executive’s employment with the Company is terminated for any reason, (i) the Executive will have 90 days to exercise the vested portion of such stock options or they will be forfeited and (ii) any unvested stock options as of such
date of termination shall be cancelled, provided, however, that if the Executive’s employment terminates by reason of death or disability, and in all events in the case of nonqualified stock options, the Executive or the Executive’s
personal representatives will have twelve (12) months in which to exercise such vested stock options. 
 (e)
Notwithstanding any termination of the Executive’s employment for any reason (with or without Cause), the Executive will continue to be bound by the provisions of the Confidentiality Agreement (as defined below). 
 (f) All payments and benefits provided pursuant to Sections 7(a) and (c) shall be conditioned upon the Executive’s
execution and non-revocation of a general release substantially in the form attached hereto as Exhibit A, at the time of termination. The Executive’s refusal to execute a general release shall constitute a waiver by the Executive of
any and all benefits referenced in Sections 7(a) an (c). The Company will not be obligated to continue any such payments to the Executive under Sections 7(a) and (c) in the event the Executive materially breaches the terms of
this Agreement or the Confidentiality Agreement (as defined below). 
 8. Confidentiality, Non-Competition and Invention Assignment
Agreement. The Company considers the protection of its confidential information and proprietary materials to be very important. Therefore, as a condition of the Executive’s employment, the Executive will be required to execute a standard
confidentiality, non-competition and invention assignment agreement substantially in the form attached hereto as Exhibit B (the “Confidentiality Agreement”) on the date hereof. Pursuant to the terms and conditions of
such Confidentiality Agreement, the Executive will also agree that in the event that for any reason the Executive’s employment with the Company is terminated (with or without Cause), for a period of twelve (12) months thereafter, the
Executive will not engage in a business activity that will be directly competitive with the business of the Company or that will result in the use or disclosure of the Company’s confidential, trade secret or proprietary information. 

 

 3 

 9. Cooperation with the Company after Termination. Following termination of this Agreement for any
reason (with or without Cause), the Executive shall fully cooperate with the Company in all matters relating to the winding up of the Executive’s services under this Agreement and the orderly transfer of such matters to any person designated by
the Company and shall promptly return to the Company all of the property of the Company and any other materials or information related to the Company, including all work product, whether finished or unfinished, prepared or produced by the Executive
for the benefit of the Company under this Agreement. 
 10. No Conflict. The Executive hereby represents and warrants to the Company
that (a) this Agreement constitutes the Executive’s legal and binding obligation, enforceable against him in accordance with its terms, (b) his execution and performance of this Agreement does not and will not breach any other
agreement, arrangements, understanding, obligation of confidentiality or employment relationship to which he is a party or by which he is bound, and (c) during the Employment Period, he will not enter into any agreement, either written or oral,
in conflict with this Agreement or his obligations hereunder. 
 11. Definitions. 
 (a) The term “Cause” shall mean (i) the Executive’s intentional, willful or knowing failure or refusal to perform the
Executive’s duties (other than as a result of physical or mental illness, accident or injury) that, in the sole discretion of the Board, may have a material adverse effect on the Company or any other material breach of this Agreement by the
Executive; (ii) dishonesty, willful or gross misconduct, or illegal conduct by the Executive in connection with the Executive’s employment with the Company which in the Board’s reasonable judgment may result in damage to the business
or reputation of the Company; (iii) the Executive’s conviction of or plea of guilty or nolo contendere to, a charge of commission of a felony (exclusive of any felony relating to negligent operation of a motor vehicle); and (iv) a
material breach by the Executive of the Confidentiality Agreement; provided, however, in the case of clauses (i) and (iv) above, the Company shall be required to give the Executive fifteen (15) calendar days prior written notice of
its intention to terminate the Executive for Cause and the Executive shall have the opportunity during such fifteen (15) day period to cure such event if such event is capable of being cured; provided, further, that in the event that the
Executive terminates his employment with the Company during such fifteen (15) day period for any reason, such termination shall be considered a termination for Cause. 
 (b) The term “Disability” shall mean if the Executive is incapacitated or disabled by accident or sickness or otherwise so as to
render him mentally or physically incapable of performing the services required to be performed by him under this Agreement for a period of 90 consecutive days or longer, or for an aggregate of 90 days during any twelve-month period. 
 (c) The term “Good Reason” shall mean (i) any adverse change in the Executive’s title or any material diminution in
the Executive’s authority or responsibilities taken as a whole, (ii) any reduction of the Executive’s base salary, other than pursuant to an across-the-board reduction in the compensation of all senior management of the Company;
provided that such reduction is proportionately equal among all such members of senior 

  

 4 

 
management, (iii) any material breach by the Company of its obligations under this Agreement, and (iv) a change without the Executive’s
consent in the principal location of the Executive’s office to an office that is more than fifty (50) miles front the Company’s proposed initial principal office location in the Bridgewater, New Jersey area, such consent not to be
unreasonably withheld; provided that in any case the Executive provides the Company with written notice of the Executive’s intention to terminate the Executive’s employment for Good Reason within thirty (30) days after the occurrence
of the event that the Executive believes would constitute Good Reason, give the Company an opportunity to cure for thirty (30) days following receipt of such notice from the Executive, if the event is capable of being cured or, if not capable
of being cured, to have the Company’s representatives meet with the Executive and the Executive’s counsel to be heard regarding whether Good Reason exists for the Executive to terminate the Executive’s employment with the Company; and

 (d) The term “person” shall mean any individual, corporation, firm, association, partnership, other legal entity
or other form of business organization. 
 12. Successors and Assigns; Entire Agreement; No Assignment. This Agreement shall bind and
inure to the benefit of the parties hereto and their respective successors or heirs, distributes and personal representatives. This Agreement and the Confidentiality Agreement contain the entire agreement between the parties with respect to the
subject matter hereof and supersede other prior and contemporaneous arrangements or understandings with respect thereto. The Executive may not assign this Agreement without the prior written consent of the Company. 
 13. Notices. All notices and other communications required or permitted hereunder or necessary or convenient in connection herewith shall be in
writing and shall be deemed to have been given when hand-delivered, mailed by registered or certified mail (three days after deposited), faxed (with confirmation received) or sent by a nationally recognized courier service, as follows (provided that
notice of change of address shall be deemed given only when received): 
  

			
	If to the Company:	  	 Aegerion Pharmaceuticals
 c/o Scheer and Company, Inc.

 250 West Main Street
 Branford, Connecticut 06405
 Attn: David I. Scheer, President

		
	If to the Executive:	  	 William J. Sasiela
 c/o Aegerion Pharmaceuticals, Inc.

 250 West Main Street
 Branford, Connecticut
06405

		
	With a copy to:	  	 The Law Office of
 Sills Cummis Epstein & Gross P.C.

 One Riverfront Plaza
 Newark, New Jersey 07102
 Telecopier No.: (973) 643-6500
 Attention: Ira A. Rosenberg,
Esq.

  

 5 

 or to such other names and addresses as the Company or the Executive, as the case may be, shall designate by notice to
each other person entitled to receive notices in the manner specified in this Section. 
 14. Changes; No Waiver; Remedies Cumulative.
The terms and provisions of this Agreement may not be modified or amended, or any of the provisions hereof waived, temporarily or permanently, without the prior written consent of each of the parties hereto. Either party’s waiver or failure to
enforce the terms of this Agreement or any similar agreement in one instance shall not constitute a waiver of its or his rights hereunder with respect to other violations of this or any other agreement. No remedy conferred upon the Company or the
Executive by this Agreement is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given hereunder or now or hereafter existing at law or in equity.

 15. Governing Law; Jurisdiction. This Agreement and (unless otherwise provided) all amendments hereof and waivers and consents
hereunder shall be governed by the law of the State of New Jersey, without regard to the conflicts of law principles. Each party hereby submits himself and itself, for the sole purpose of this Agreement, the Confidentiality Agreement, and any
controversy arising hereunder and thereunder, to the exclusive jurisdiction of the state and Federal courts located in the State of New Jersey, and waives any objection (on the grounds of lack of jurisdiction, forum non conveniens or otherwise) to
the exercise of such jurisdiction over it by any such court in the State of New Jersey. Each party hereby agrees that service of process may be served on him or it by certified mail, return receipt requested, or overnight courier, sent to address of
such entity listed in Section 13 above (or such other address as any such party notifies the others thereof by written notice). THE PARTIES HEREBY EXPRESSLY WAIVE THEIR RIGHTS TO HAVE A JURY TRIAL. 
 16. Severability. The Executive and the Company agree that should any provision of this Agreement be judicially determined invalid or
unenforceable, that portion of this Agreement may be modified to comply with the law. The Executive and the Company further agree that the invalidity or unenforceability of any provision of this Agreement will not affect the validity or
enforceability of its remaining provisions. 
 17. Execution of Other Agreements. The Confidentiality Agreement is hereby incorporated
into this Agreement in its entirety and is made an integral part of this Agreement. 
 18. Headings; Counterparts. All section
headings are for convenience only. This Agreement may be executed in several counterparts, each of which is an original. 
 19. Due
Diligence. This Agreement shall be subject to and contingent upon the satisfactory results of the Company’s due diligence, such as a medical examination, satisfactory reference, background and education verification. 
  

 6 

 IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of the date first above
written. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	/s/ Gerald Wisler
		 	Gerald Wisler
	
	EXECUTIVE:
	
	/s/ William J. Sasiela
	William J. Sasiela

  

 7 

 EXHIBIT A 
 GENERAL RELEASE OF CLAIMS 
 For and in consideration of the payments and other benefits
described in the Employment Agreement dated as of                     , 2005 (the “Agreement”) by and among Aegerion
Pharmaceuticals, Inc. (the “Company”), and                     (the “Employee”) and for other good and valuable
consideration, the Employee hereby releases the Company and its respective divisions, operating companies, affiliates, subsidiaries, parents, branches, predecessors, successors, assigns, officers, directors, trustees, employees, agents,
shareholders, administrators, representatives, attorneys, insurers and fiduciaries, past, present and future (the “Released Parties”) from any and all claims of any kind arising out of or related to the Employee’s employment with the
Company, the Employee’s separation from employment with the Company or derivative of the Employee’s employment, which the Employee now has or may have against the Released Parties, whether known or unknown to the Employee, by reason of
facts which have occurred on or prior to the date that the Employee has signed this General Release of claims. Such released claims include, without limitation, any alleged violation of the Age Discrimination in Employment Act, as amended, the Older
Worker Benefits Protection Act; Title VII of the Civil Rights of 1964, as amended; Sections 1981 through 1988 of Title 42 of the United States Code; the Civil Rights Act of 1991; the Equal Pay Act; the Americans with Disabilities Act; the
Rehabilitation Act; the Family and Medical Leave Act; the Fair Labor Standards Act; the Employee Retirement Income Security Act of 1974 as amended; the Worker Adjustment and Retraining Notification Act; the National Labor Relations Act; the Fair
Credit Reporting Act; the Occupational Safety and Health Act; the Uniformed Services Employment and Reemployment Act; the Employee Polygraph Protection Act; the Immigration Reform Control Act; the retaliation provisions of the Sarbanes-Oxley Act of
2002; the Federal False Claims Act; the New Jersey Law Against Discrimination; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee Protection Act; the New Jersey Family Leave Act; the New Jersey Wage and Hour Law; the New
Jersey Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey Smokers’ Rights Law; the New Jersey Workers’ Compensation Law (and including any and all amendments to the above) and/or any other alleged violation of
any federal, state or local law, regulation or ordinance, and/or contract or any other alleged violation of any federal, state or local law, regulation or ordinance, and/or contract or implied contract or tort law or public policy or whistleblower
claim, having any bearing whatsoever on the Employee’s employment by and the termination of the Employee’s employment with the Company, including, but not limited to, any claim for wrongful discharge, back pay, vacation pay, sick pay,
wage, commission or bonus payment, money or equitable relief or damages of any kind, attorneys’ fees, costs, and/or future wage loss. 
 It is understood that this General Release of Claims is not intended to and does not affect or release any future rights or any claims arising after the date hereof. 
 The Employee understands that the consideration provided to him under the terms of the Agreement or otherwise does not constitute any admission by the
Company that it has violated any law or legal obligation. 

 The Employee agrees, to the fullest extent permitted by law, that he will not commence, maintain,
prosecute or participate in any action or proceeding of any kind against the Company based on any of the claims waived herein occurring up to and including the date of his signature. The Employee represents and warrants that he has not done so as of
the effective date of this General Release of Claims. Notwithstanding the foregoing agreement, representation and warranty, if the Employee violates any of the provisions of this paragraph, the Employee agrees to indemnify and hold harmless the
Company from and against any and all costs, attorneys’ fees and other expenses authorized by law which result from, or are incident to, such violation. This paragraph is not intended to preclude the Employee from (1) enforcing the terms of
the Agreement; (2) challenging the knowing and voluntary nature of this General Release of Claims; or (3) filing a charge or participating in any investigation or proceeding conducted by the Equal Employment Opportunity Commission.

 The Employee further agrees to waive his right to any monetary or equitable recovery should any federal, state or local administrative
agency pursue any claims on his behalf arising out of or related to his employment with and/or separation from employment with the company and promises not to seek or accept any award, settlement or other monetary or equitable relief from any source
or proceeding brought by any person or governmental entity or agency on his behalf or on behalf of any class of which he is a member with respect to any of the claims he has waived. 
 The Employee acknowledges and agrees that the Employee has read this General Release of Claims carefully, and acknowledges that he has been given at
least twenty one (21) days from the date of receipt of this General Release of Claims to consider all of its terms and has been advised to consult with any attorney and any other advisors of the Employee’s choice prior to executing this
General Release of Claims. The Employee fully understands that, by signing below, the Employee is voluntarily giving up any right which the Employee may have to sue or bring any other claims against the Released Parties, including any rights and
claims under the Age Discrimination in Employment Act. The terms of this General Release of Claims shall not become effective or enforceable until eight (8) days following the date of its execution by the Employee, during which time the
Employee may revoke the Agreement. The Employee may revoke the Agreement by notifying the company in writing (to the attention of the Executive chairman with a copy to the Vice President of Legal Affairs). For the Employee’s revocation to be
effective, written notice must be received by the Company no later than the close of business on the eighth (8th) day after the Employee signs this General Release of Claims. The terms of this offer to provide the payments and other benefits
described in Section 7(a) of the Agreement, will expire if not accepted during the twenty one (21) day review period. 
 The
Employee agrees to keep confidential all information contained in this General Release of Claims and relating to this General Release of Claims, except (1) to the extent the Company consents in writing to such disclosure; (2) if the
Employee is required by process of law to make such disclosure and the Employee promptly notifies the Company of his receipt of such process; or (3) because the Employee must disclose certain terms on a confidential basis to his financial
consultant, attorney or spouse. 
 This General Release of Claims shall be construed and enforced in accordance with, and governed by, the
laws of the State of New Jersey, without regard to principles of conflict of laws. 

  

 2 

 
If any clause of this General Release of Claims should ever be determined to be unenforceable, it is agreed that this will not affect the enforceability of
any other clause or the remainder of this General Release of Claims. 
 This General Release of Claims is final and binding and may not be
changed or modified except as set forth herein or in a writing signed by both parties. The parties have executed this General Release of Claims with full knowledge of any and all rights they may have, and they hereby assume the risk of any mistake
in fact in connection wit the true facts involved, or with regard to any facts which are now unknown to them. 
 By signing this General
Release of claims, the Employee acknowledges that: (1) he has read this General Release of Claims completely; (2) he has had an opportunity to consider the terms of this General Release of Claims; (3) he has had the opportunity to
consult with an attorney of his choosing prior to executing this General Release of Claims to explain this General Release of Claims and its consequences; (4) he knows that he is giving up important legal rights by signing this General Release
of Claims; (5) he has not relied on any representation or statement not set forth in this General Release of Claims; (6) he understands and means everything that he has said in this General Release of Claims, and he agrees to all its
terms; and (7) he has signed this General Release of Claims voluntarily and entirely of his own free will. 
  

					
	  	 		 	  
	Date	 		 	[Employee]
			
	  	 		 	  
	Date	 		 	Aegerion Pharmaceuticals, Inc.

  

 3 

 EXHIBIT B 
 CONFIDENTIALITY AGREEMENT 
 This CONFIDENTIALITY AGREEMENT (this “Agreement”), effective as of the date set
forth last below, is made by and between the undersigned counter party (“Recipient”) and Aegerion Pharmaceuticals, Inc. (“Aegerion”). In consideration of the mutual agreements and other provisions of this Agreement, the parties
hereto agree as follows: 
 1. Scope of Confidential Information. 
 1.1 “Confidential Information” means, subject to the exceptions set forth in Section 1.2, any information or data or materials, regardless of whether it is in tangible form, that is disclosed or
otherwise made available by or on behalf of Aegerion to Recipient before or during the term of this Agreement. “Confidential Information” includes but is not limited to: (a) patent and patent applications; (b) trade secrets;
(c) third party information; and (d) ideas, gene sequences, cell lines, samples, chemical compounds, clinical data, clinical trial design, assays, biological materials, techniques, sketches, drawings, works of authorship, models,
inventions, know-how and processes pertaining to the current, future and proposed business, products and services of Aegerion. 
 1.2 “Confidential
Information” shall not include any information that: (a) appears in issued patents or printed publications in integrated form or which otherwise is or becomes generally known in the trade other than through Recipient’s failure to
observe any or all terms and conditions hereof; provided that the foregoing shall not be interpreted to create any express or implied license, or the right to obtain a license, to any patents which may be issued to Aegerion; (b) is made
available to Recipient by a third party who is lawfully in possession of such information, and who is not in violation of any confidentiality obligation in favor of Aegerion; or (c) Recipient can show by written record was in available to or in
possession of Recipient (free of any confidentiality obligation in favor of Aegerion known to Recipient at the time of disclosure or availability) prior to disclosure of such information by Aegerion to Recipient, provided that Counter must promptly
notify Aegerion of any prior knowledge in the manner provided in Section 2.4 below. Notwithstanding the foregoing, (i) technical information disclosed under this Agreement shall not be deemed to be within the foregoing exceptions merely
because such information is embraced by more general information in the public domain or in Recipient’s possession, and (ii) any combination of features shall not be deemed to be within the foregoing exceptions merely because individual
features are in the public domain or in Recipient’s possession, but only if the combination itself and its principle of operation are in the public domain or in Recipient’s possession. 
 2. Use and Disclosure of Confidential Information. 
 2.1
Recipient shall only use the Confidential Information internally solely for the purpose of evaluating a potential business relationship between Recipient and Aegerion (the “Permitted Purpose”). Recipient must keep secret and shall never,
without the prior written consent of Aegerion, directly or indirectly, disclose, publish, divulge, furnish or make accessible to anyone all or any portion of the Confidential Information, other than furnishing such Confidential Information to
(a) Recipient’s employees and consultants who are required to have access to such Confidential Information in connection with the Permitted Purpose, and (b) Recipient’s professional, licensed advisers (i.e., lawyers and
accountants), in each case, during the time that Recipient is permitted to retain such Confidential Information hereunder; provided that any and all such employees, consultants are bound by written agreements or, in the case of professional
advisers, ethical duties, respecting the Confidential Information in the manner set forth in this Agreement. 
 2.2 Recipient shall use at least reasonable
care and adequate measures to protect the confidentiality of the Confidential Information of Aegerion and to ensure that any Confidential Information of Aegerion is not disclosed or otherwise made available to other persons or used in violation of
this Agreement. Without limiting any of the foregoing, such measures shall be at least the equivalent of measures which Recipient uses to protect Recipient’s own most valuable proprietary information. 
 2.3 In the event that Recipient is required by law to make any disclosure of any of the Confidential Information of Aegerion, by subpoena, judicial or administrative
order or otherwise, Recipient shall first give written notice of such requirement to Aegerion, and shall permit Aegerion to intervene in any relevant proceedings to protect its interests in the Confidential Information, and provide full cooperation
and assistance to Aegerion in seeking to obtain such protection. 
 2.4 Recipient agrees to notify Aegerion promptly in writing if (a) Recipient becomes
aware of any breach of this Agreement with respect to the Confidential Information of Aegerion in Recipient’s possession; (b) subsequent to disclosure of any 

  

 B-1 

 CONFIDENTIALITY AGREEMENT 
  

 
Confidential Information by Aegerion, information is disclosed to Recipient in the manner described in Section 1.2; or (c) upon disclosure of
Confidential Information by Aegerion, Recipient has prior knowledge of the same. 
 2.5 Recipient shall not embody any of the Confidential Information of
Aegerion in any of Recipient’s products, processes or services, or duplicate or exploit any of such Confidential Information in Recipient’s business, or otherwise use any of the Confidential Information for any purpose other than for the
Permitted Purpose. 
 3. Certain Rights and Limitations. 
 3.1 All Confidential Information shall remain the property of Aegerion. The provision of Confidential Information hereunder shall not transfer any right, title or interest in such information to Recipient. Aegerion does not grant Recipient
any express or implied right to or under Aegerion’s or another party’s patents, copyrights, trademarks, trade secret information or other proprietary rights. 
 3.2 Recipient shall not remove, overprint or deface any notice of confidentiality, copyright, trademark, logo, legend or other notices of ownership or confidentiality from any originals or copies of Confidential
Information it obtains from Aegerion. 
 3.3 This Agreement imposes no obligations on either party to exchange any Confidential Information or to purchase,
sell, license, transfer or otherwise transact in any technology, services or products. 
 3.4 Confidential Information disclosed by the parties under this
Agreement may be subject to export controls under the laws of the United States. Each party shall comply with such laws and agrees not to knowingly export, re-export or transfer Confidential Information of the other party without first obtaining all
required United States authorizations or licenses. 
 3.5 All tangible embodiments of the Confidential Information of Aegerion (e.g., drawings,
memoranda and notes) and all copies thereof, whether in hard-copy or machine-readable form and whether supplied by Aegerion or made by or for Recipient (collectively, the “Tangible Embodiments”), shall at all times be and remain the
exclusive property of Aegerion. 
 3.6 Recipient shall provide upon Aegerion’s request a certification that access and use is being controlled in
accordance with this Agreement. Aegerion shall have the right to audit to verify compliance with this Agreement. 
 4. Remedies. Recipient
acknowledges that a breach by it of any of the terms of this Agreement would cause irreparable harm to Aegerion for which Aegerion could not be adequately compensated by money damages. Accordingly, Recipient agrees that, in addition to all other
remedies available to Aegerion in an action at law, in the event of any breach or threatened breach by Recipient of the terms of this Agreement, Aegerion shall, without the necessity of proving actual damages or posting any bond or other security,
be entitled to temporary and permanent injunctive relief, including, but not limited to, specific performance of the terms of this Agreement. 
 5.
Termination. 
 5.1 This Agreement shall remain in effect until it is terminated by either party with thirty (30) days prior written notice.
The terms and conditions of this Agreement shall survive any such termination with respect to Confidential Information that is disclosed prior to the effective date of termination. 
 5.2 Upon the earlier of (a) the termination of this Agreement, (b) Aegerion’s written request or (c) such time as Recipient no longer requires the Confidential Information for the Permitted
Purpose, Recipient agrees to promptly return to Aegerion or destroy all Confidential Information and any Tangible Embodiments that are in the possession of Recipient and to certify the return or destruction of all such Confidential Information and
embodiments. 
 6. Warranty. NO WARRANTY IS MADE BY EITHER PARTY UNDER THIS AGREEMENT. ANY INFORMATION EXCHANGED UNDER THIS AGREEMENT IS
PROVIDED “AS IS.” 
 7. Miscellaneous. This Agreement does not create any agency or partnership relationship between the parties
hereto. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey governing such agreements, without regard to conflicts-of-law principles. The sole and exclusive jurisdiction and venue for any
litigation arising out of this Agreement shall be an appropriate federal or state court located in the State of New Jersey, and the parties agree not to raise, and waive, any objections or defenses based upon venue or forum non conveniens. This
Agreement contains the complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings whether written or oral, express or implied. Except where expressly indicated
otherwise, the words “written” or “in writing” shall include, but not be limited to, written or printed documents, in any format now know or later developed including electronic and facsimile transmissions and computer disks or
tapes 

  

 B-2 

 CONFIDENTIALITY AGREEMENT 
  

 
(whether machine or user readable). If any provision of this Agreement is held invalid, illegal or unenforceable by a court of competent jurisdiction, such
shall not affect any other provision of this Agreement, which shall remain in full force and effect. No amendment or alteration of the terms of this Agreement shall be effective unless made in writing and executed by both parties hereto. A failure
or delay in exercising any right in respect to this Agreement shall not be presumed to operate as a waiver, and a single or partial exercise of any right shall not be presumed to preclude any subsequent or further exercise of that right or the
exercise of any other right. Any modification or waiver of any provision of this Agreement shall not be effective unless made in writing. Any such waiver shall be effective only in the specific instance and for the purpose given. 
 IN WITNESS WHEREOF, the parties have caused this Confidentiality Agreement to be executed below by their duly authorized signatories. 
  

									
	 	 		 	AEGERION PHARMACEUTICALS, INC.
					
	By:	 	 	 		 	By:	 	 
	Name:	 		 	Name:
	Title:	 		 	Title:
	Date:	 		 	Date:
			
	Address for notices to Recipient:	 		 	Address for notices to Aegerion:

  

 B-3 

 Amendment to Employment Agreement 
 This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT dated as of February 7, 2007 is between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and William J. Sasiela (the
“Executive”). 
 WHEREAS, the Executive is currently employed as a senior executive of the Company under an Employment Agreement dated
December 1, 2005 (the “Agreement”); 
 WHEREAS, Section 7 of the Agreement contains certain severance provisions in respect of the
Executive; and 
 WHEREAS, the parties hereto consider it appropriate that the Agreement be amended pursuant to Section 14 of the Agreement to prevent
adverse tax treatment of severance payments to the Executive upon termination. 
 NOW, THEREFORE, the Company and the Executive agree to the following
amendment to the Agreement. Defined terms used in this Amendment shall have the same meanings as in the Agreement. 
  

	1.	Definitions. Capitalized terms used in this Amendment and not otherwise defined herein shall have the meaning given to such terms in the Agreement. 

  

	2.	Termination. Section 7 of the Agreement is amended adding a new subsection (g) as follows: 

 Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s termination of employment, the Executive is considered
a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”), and if any payment that the Executive becomes entitled to under this Agreement is
considered deferred compensation subject to interest and additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, then no such payment shall be payable prior to
the date that is the earliest of (i) six months and one day after the Executive’s date of termination, (ii) the Executive’s death, or (iii) such other date as will cause such payment not to be subject to such interest and
additional tax, and the initial payment shall include a catch-up amount covering amounts that would otherwise have been paid during the first six-month period but for the application of this Section 7(g). 
  

	3.	Scope of Amendment. Except as expressly set forth in this Amendment, the Agreement remains in effect without modification. 

  

	4.	Counterparts. This Amendment may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by different parties hereto in separate
counterparts, each of which when executed shall be deemed to be an original but all of which when taken together shall constitute one and the same agreement. 

	

 IN WITNESS WHEREOF, the Executive and Company have executed this Amendment as of the date set forth above. 
  

			
	 EXECUTIVE

	
	 /s/ William J. Sasiela

	 Name:
	 	William J. Sasiela
	
	 AEGERION PHARMACEUTICALS, INC.

	
	 /s/ Gerald Wisler

	 By:
	 	Gerald Wisler
	 Title:
	 	President and CEOEmployment Agreement with Christine Pellizzari

 Exhibit 10.7 
 July 31, 2007 
 Personal and Confidential 
 Christine Pellizzari 
 Post Office Box 505 
 Brookside,
New Jersey 07926 
 Dear Christine: 
 Aegerion Pharmaceuticals,
Inc. (“Aegerion” or the “Company”) is pleased to offer you the full-time position of Vice President, General Counsel and Secretary, reporting to Jerry Wisler, President and CEO. We are excited about the prospect of you joining
our team, and look forward to the addition of your professionalism and experience to help the Company achieve its goals. You are scheduled to begin your “at-will” employment with the Company on or before June 15, 2007. 
 Compensation and Benefits 
 You will be paid an initial
biweekly salary of $8653.85 ($225,000 on an annualized basis) (the “Base Salary”), which will be paid in accordance with the Company’s normal payroll practices as established or modified from time to time. You are entitled to 4 weeks
vacation per full calendar year, which shall accrue on a monthly basis in accordance with company policy. For calendar year 2007, you will receive and immediately accrue 4 weeks vacation, and be allowed to take such vacation at mutually agreed upon
times. 
 In addition to your Base Salary, you will be eligible to earn a merit bonus of up to 25% of your Base Salary. The magnitude of the bonus, if any,
will be determined by the Company’s Board of Directors (the “Board”) and your manager in their sole discretion, based upon your achievement of a series of performance milestones. Your achievement of such milestones shall be determined
by the Board and your manager in their sole discretion. The bonus, if any, shall be paid at a time and in a manner as determined by the Company in its sole discretion; provided, however, the bonus will be paid at the same time as bonuses are
generally paid to senior executives. You must be employed by Aegerion at the time of any such bonus payment in order to be eligible for any such payment. Notwithstanding anything else to the contrary, for calendar year 2007 and assuming that you
remain continually employed by the Company through December 31, 2007, a portion of your 2007 bonus in the amount of 828,125 will be guaranteed as a “sign-on bonus, which will be payable at the time other bonuses are paid. Any remaining
bonus payment for 2007 will be based on your achievement of performance milestones. 
 In addition, you will be granted an option to purchase 275,000 shares
of the Company’s common stock under the existing stock option program. As mentioned, these shares are subject to a reverse stock split prior to pricing. The current discussion is a 1 for 1.4715 reverse split, which would equate to approximately
186,880 shares. The exercise price of the options will be at fair market value on your first date of employment. The terms of this grant shall be subject to and governed by the Company’s stock plan and a stock option agreement between you and
the Company. The Company agrees that you will receive stock options on the same terms and conditions as other senior executives. 

 You will also be eligible to participate in the Company’s benefits programs to the same extent as, and subject to
the same terms, conditions and limitations applicable to, other employees of the Company of similar rank and tenure. These benefits presently include: eligibility to accrue vacation time, paid holidays, a 401(k) plan and contributory
health/dental/vision insurance. For a more detailed understanding of the benefits and the eligibility requirements, please consult the summary plan descriptions for the programs which will be made available to you during your new hire orientation.
Subject to the terms set forth herein, please note that the Company may modify compensation and benefits at its discretion. 
 The Company agrees to provide
you with indemnification rights on the same terms as other officers of the Company and to the fullest extent permitted by the terms of the Company’s by-laws. In this regard, the Company agrees to provide you with the indemnification agreement
attached hereto as Exhibit C. 
 Certain Conditions of Employment 
 You will be required to sign the attached Business Protection Agreement as a condition of your employment with the Company. This Agreement is attached hereto as Exhibit A. You acknowledge that the
Business Protection Agreement shall remain in full force and effect regardless of any change in your position, compensation or any other term and conditions of your employment with the Company in accordance with the terms contained
therein. 
 In addition, you represent and warrant that your employment with the Company and the performance by you of your duties as an employee of the
Company do not and will not breach or contravene (i) any agreement or contract (including, without limitation, any employment or consulting agreement, any agreement not to compete or any confidentiality or nondisclosure agreement) to which you
are a party; or (ii) any obligation you may otherwise have under applicable law to any former employer or to any person to whom you have provided consulting services. You further represent and warrant that you have delivered or disclosed, as
the case may be, to the Company all relevant provisions in agreements, contracts and obligations relevant to clauses (i) and (ii) above. Addition, you must execute the document attached hereto as Exhibit B as a condition of your
employment. 
 Please note that as conditions of this offer and your employment you will need to complete an employment application, background and/or
reference check to the Company’s satisfaction, and you will need to execute the forms necessary for the processing of such background check. Moreover, please bring with you on your first day of employment for purposes of completing the 1-9 form
sufficient documentation to demonstrate your eligibility to work in the United States. This verification must occur by the third day of your employment. 
 Eligibility for Severance Upon Termination. You may be eligible to receive severance payments following the termination of your at-will employment with the Company in accordance with, and as governed by, the terms of the Agreement to Pay
Severance, which is attached hereto as Exhibit C. 

 General 
 Please note that this letter is a summary of your initial employment relationship with the Company. Because you are employed on an at-will basis, Company may modify the terms of your employment at any time and for any or not reason. Along
these lines, please note that nothing in this offer letter is a promise or guarantee of employment for any specific period of time or continued employment. In this regard, the Company has found that an at-will relationship is in the best interests
of both the Company and its employees. As an at-will employee, either you or the Company can terminate your employment at any time and for any reason or no reason, with or without prior notice, subject to any severance obligations that may exist
under the terms of that certain Agreement to Pay Severance. 
 We look forward to having you join Aegerion. We hope you will be a very valuable contributor
to our team going forward. Please provide a response to this letter within seven (7) days. 
 Sincerely, 
  

			
	 /s/ Gerald Wisler

	By:	 	Gerald Wisler
	Title:	 	President and CEO

 Enclosures 

 Exhibit A 
 BUSINESS PROTECTION AGREEMENT 
 This Agreement is entered by and between Aegerion
Pharmaceuticals, Inc. (hereinafter the “Company”), and Christine Pellizzari (hereinafter the “Employee”). 
 WHEREAS,
Employee acknowledges that he/she will be provided with the Company’s trade secrets and/or valuable confidential business information, and, in addition, will develop, substantial relationships with, and be introduced to, prospective and
existing customers and clients of the Company, and, as a result, shall benefit from the Company’s good will; 
 WHEREAS, Employee
acknowledges that he/she will receive training from the Company; 
 WHEREAS, this Agreement is a material part of the consideration of
Employee’s employment with the Company, and the Company would not have hired Employee but for Employee’s agreement to the terms and conditions of this Agreement; 
 WHEREAS, the Company is willing to employ Employee, and Employee is willing to accept his/her employment with the Company, upon the terms and subject to
the conditions hereinafter set forth herein; 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this
Agreement, Employee’s employment, and the compensation paid to Employee by the Company; the parties agree as follows: 
 1.
Employment At Will: 
 (a) Employee understands that neither this Agreement nor any other document or representation regarding
employment with the Company constitutes an implied or written employment contract for continued employment with the Company. Rather, Employee’s employment with the Company is on an “at-will” basis. Accordingly, Employee understands
and agrees that either Employee or the Company may terminate Employee’s employment at any time and for any reason, with or without cause and with or without notice. 
 (b) Employee will perform and carry out such duties and/or responsibilities as may from time to time be assigned to Employee by the Company in its sole discretion. The Company may also modify or change Employee’s
position, duties, compensation and responsibilities as it deems appropriate in its sole discretion. Any such changes shall not change Employee’s obligations as set forth herein. During his/her employment with the Company, Employee shall devote
his/her full business time and attention to the affairs of the Company. 
  

 2. Employee’s Representations: 
 (a) Employee represents and warrants that he/she is qualified and uniquely skilled to perform the services required by the Company in accordance with the
standards of good professional practice and that Employee possesses all skills, qualifications and experience described in any application and/or resume submitted by Employee. Employee further understands and acknowledges that the Company relied
upon these representations in hiring Employee and that the Company would not have hired Employee but for these representations. 
 (b)
Employee represents that Employee’s employment with the Company and Employee’s performance of all of the terms of this Agreement do not, and will not, breach any agreement with any third party. Employee has not entered into, and Employee
shall not enter into, any agreement either written or oral in conflict herewith. 
 (c) Employee acknowledges that he/she owes to Company a
fiduciary duty of loyalty during the term of Employee’s employment and as may be otherwise provided by applicable law. 
 (d) If
Employee is terminated for any reason, Employee will be able to earn a livelihood due to his/her sufficient capabilities without violating this Agreement. Employee understands that his/her ability to earn a livelihood without violating this
Agreement is a material condition of his/her employment with the Company. 
 3. Non-Solicitation of Employees/Contractors: 

Employee agrees that during the course of his/her employment with the Company, and for the period of twelve (12) months following the termination
of Employee’s employment (the “Restricted Period”), regardless of the reason for the termination, Employee will not solicit, recruit or induce, in any manner, whether directly or indirectly, any “Person” to leave his or her
employment or engagement with the Company. “Person” means any person who (a) is employed (whether as an agent, representative, contractor or consultant by the Company) at the time this Agreement is terminated, (b) was employed by
the Company during the year preceding termination of this Agreement, or (c) is employed by the Company during the Restricted Period. 
 4. Non-Solicitation of/Non-Interference with Customers: 
 Employee agrees that during the Restricted Period, regardless of
the reason for the termination, Employee will not, in any manner, on his own behalf or on behalf of another: 
 (a) solicit or do business
with any customer or prospective customer of the Company with whom Employee had professional “Contact” during Employee’s employment with the Company, for the purpose of providing or seeking to provide any products or services that
relate, directly or indirectly, to the Company’s “Business” (as Defined in Section 5) (the “Services”). “Contact” means any interaction, whether direct or indirect, between Employee and a Company 

  

 2 

 
customer or prospective customer that takes place in an effort to establish, maintain, service, provide Services and/or further a business relationship on
behalf of the Company; 
 (b) solicit or do business with any customer or prospective customer of the Company about whom Employee obtained
information, or became familiar with through Confidential Information (as defined in Section 6), during Employee’s employment with the Company, for the purpose of providing or seeking to provide Services; 
 (c) solicit or do business with any person or entity who has been a customer of the Company within die twenty-four (24) months preceding the date of
Employee’s termination for the purpose of providing or seeking to provide Services; and 
 (d) interfere in any way with the
Company’s relationship with any customer or prospective customer. 
 5. Noncompetition: 
 (a) Employee acknowledges that during his/her employment with the Company he/she shall be engaged in the Company’s “Business”, which
includes, but is not limited to, Cardiovascular and Metabolic drug development and commercialization (the “Business”). Employee also acknowledges and recognizes the highly competitive nature of the industry in which the Company is
involved, and agrees that lie/she shall have access to the Company’s Confidential Information (as defined in Section 6), shall benefit from the Company’s goodwill and shall obtain a competitive advantage as to the Company, its
customers and prospective customers and its employees. 
 (b) Accordingly, ancillary to the agreement to hire Employee and provide Employee
with Confidential Information set forth in Section 6, Employee agrees that, during the Restricted Period, regardless of the reason for the termination, Employee shall not, directly or indirectly, anywhere in the world, alone or as a partner,
joint venturer, consultant, officer, director, employee, agent, or stockholder of any company or business organization or otherwise, engage in any business activity that (i) relates to the Business, (ii) is in competition with the
Business, including, but not limited to, any Company product or service developed or being developed, planned or being planned, drafted or being drafted, marketed or being marketed, distributed or being distributed, sold or being sold, or otherwise
provided by the Company; provided however, that the record or beneficial ownership by Employee of 1% or less of the outstanding publicly traded capital stock of any such competing company shall not be deemed in and of itself to violate this
Section, so long as Employee exercises no operational or strategic control over such company. 
 6. Confidentiality: 
 (a) During Employee’s employment with the Company and at any time thereafter, Employee shall not disclose or use or otherwise exploit, for his/her
own benefit, or for the benefit of any other person or entity, any Confidential Information (as defined in Section 6(b)). Employee acknowledges that all Confidential Information, together with all notes and records relating thereto and all
copies, electronic versions and facsimiles thereof, are the exclusive property of the Company. Employee shall return all such Confidential Information to the 

  

 3 

 
Company promptly upon request by the Company and, in any event, promptly upon any termination or expiration of this Agreement. 
 (b) “Confidential Information” shall mean any of the trade secrets or confidential information concerning the organization, business or
finances of the Company and/or of any third party, including, but not limited to, clients and vendors, which the Company is under an obligation to keep confidential. Such Confidential Information shall include, but is not limited to, trade secrets
or confidential information respecting existing and future products and services, designs, methods, formulas, drafts of publications, research, clinical trial data, know-how, techniques, systems, databases, processes, software programs or code,
developments or experimental work, works of authorship, customer information, including, but not limited to any compilations of past, existing or prospective customers, customer proposals or agreements between customers and the Company, status of
customer accounts or credit, control sheets, sales techniques, or related information about actual or prospective customers, business plans, marketing plans, sales techniques, projects, the Company’s salary and/or pay rates, other Company
personnel information, and all other plans and/or proposals. “Confidential Information” shall not include information that (i) is or becomes a matter of public knowledge through no fault or without violation of any duty of
confidentiality of the Employee; or (ii) is rightfully received by the Employee from a third party without a duty of confidentiality. 
 (c) Employee agrees that during Employee’s employment Employee shall not make, use or permit to be used any Company Documentation (as defined in Section 6(d)) otherwise than for the benefit of the Company. Employee further agrees
that Employee shall not, after the termination of Employee’s employment for any reason, use or permit others to use any such Company Documentation, it being agreed that all Company documentation shall be and remain the sole and exclusive
property of the Company. Immediately upon the termination of Employee’s employment for any reason Employee shall deliver all Company Documentation, and all copies thereof, to the Company, at its main office. 
 (d) The term “Company Documentation” shall mean notes, drafts, research, memoranda, manuscript, reports, proposals, business plans, marketing
plans, lists, correspondence, records, drawings, sketches, blueprints, specifications, software programs, data, documentation or other materials of any nature and in any form, whether written, printed, or in digital format or otherwise, relating to
any matter within the scope of the business of the Company or concerning any of its dealings or affairs. 
 (e) Employee recognizes that the
Company has received and in the future will receive from third parties, including, but not limited to, clients and vendors, their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality.
of such information and to use it only for certain limited purposes. Employee agrees that Employee owes the Company and such third parties, during the tern of Employee’s employment and thereafter, regardless of the reason for Employee’s
termination of employment, a duty to hold all such confidential or proprietary information in the strictest of confidence and not to disclose it to any person, entity or corporation (except as necessary in carrying out Employee’s work for the
Company consistent with the Company’s agreement with such third party) or to use it for the benefit of anyone other than for the Company or such third party (consistent with the 

  

 4 

 
Company’s agreement with such third party) without the express written authorization of the Company. 
 (f) The confidentiality, property, and proprietary rights protections set forth in this Agreement are in addition to, and not exclusive of, any and all
other rights to which the Company is entitled under federal and state law, including, but not limited to, rights provided under copyright laws, trade secret and confidential information laws, and laws concerning fiduciary duties. 
 (g) Employee agrees that Employee will not, during Employee’s employment with the Company, use or disclose any proprietary information or trade
secrets of Employee’s former employers or of any other third parties, and that Employee will not bring onto the premises of the Company any unpublished document or any property belonging to Employee’s former employers or of any other third
party, unless consented to in writing by said employers or third parties. By executing this Agreement, Employee indicates his/her understanding that any proprietary information or trade secrets of any prior employer is not necessary to his/her
employment by the Company. Moreover, Employee acknowledges that the Company is directing him/her not to rely on such proprietary information or trade secrets in the course of his/her employment, not to disclose such information to the Company, and
not to otherwise use such information. 
 (h) Employee specifically agrees and acknowledges that the obligations of confidentiality described
in this Section are retroactive to the beginning of his/her performance of any services for the Company and shall apply to Confidential Information received by him/her at any time. 
 (i) Employee agrees and acknowledges that during his/her employment with the Company and for the Restricted Period, Employee shall inform each
prospective new employer Employee may have, prior to accepting employment, of the existence of this Agreement, and shall provide each prospective employer with a copy of this Agreement. Employee agrees and acknowledges that the Company has the right
to independently contact any potential or actual future employer of mine to notify the future employer of my obligations under this Agreement and provide such future employer with a copy of this Agreement. The Company shall be entitled to notify
such actual or potential future employer of the Company’s understanding of the requirements of this Agreement and what steps, if any, the Company intends to take to insure compliance with or enforcement of this Agreement. In addition, Employee
shall execute the certification attached hereto as Exhibit I upon termination. 
 (j) Employee further understands and agrees that in
order for Company to protect its Confidential Information, the Company may at any time in its discretion, either with or without notice, audit and/or review files, materials and documents, computer hardware or software, email or voice message
systems which are provided to, utilized by and/or created by the Employee in the course of the performance of the Employee’s duties under this Agreement. 
 7. Ownership of Information and Documents: 
 (a) For purposes of this Agreement, “Work
Product” shall mean all information, including but not limited to, data, materials, text, drawings, specifications, reports, notes, 

  

 5 

 
documentation, computer programs, inventions (whether or not patentable), records, business information, trade secrets and all works of authorship
(including, without limitation, all copyrights and trademarks existing therein), conceived and/or reduced to practice, created or developed by Employee, alone or jointly with others, related to the business of Company or any client or conceived
during work hours, at any time during Employee’s employment by the Company. Employee shall promptly and fully disclose to the Company any and all of such Work Product. All Work Product, whether preliminary or final, tangible or intangible,
shall be and remain the sole property of Company (unless assigned or licensed by the Company), and shall not be photocopied, reproduced or removed from the premises of Company or any client except as required to perform duties under this Agreement
or with the written permission of the client. All Work Product shall be delivered either to Company, or to the client upon request and, in any event, upon any termination or expiration of this Agreement. Employee hereby releases any right, title and
interest Employee may have to any Work Product during the term of this Agreement. To the extent the Work Product is not, by operation of law, considered work for hire for the Company, or ownership of all right, title and interest of the intellectual
property rights in the Work Product has not otherwise vested exclusively in Company, Employee hereby irrevocably assigns to Company, without further consideration, Employee’s entire right, title, and interest in and to such Work Product.

 (b) In this regard, Employee has attached hereto, as Exhibit II, a list describing with particularity all intellectual property,
including, but not limited to, property inventions, copyrights, copyright applications or registrations, original works of authorship, developments improvements, patents, patent applications, trademarks, trademark applications, trade names or trade
secrets which were created or owned by Employee prior to the commencement of his employment and which belong solely to Employee or belongs to Employee jointly with another, which relate in any way to any of the Company’s Businesses, products or
research and development (collectively referred to as “Prior Inventions”), and which are not assigned to the Company hereunder, or, if no such list is attached, Employee represents that there are no such Prior Inventions. If, in the course
of employment, Employee agrees to incorporate into a Company product, process or machine a Prior Invention owned by him or in which he has an . interest, absent a prior written agreement or license between himself and the Company for such
incorporation of the Prior Invention into a Company product, process or machine, then the Company is hereby granted and shall have anon-exclusive, royalty-free, irrevocable, perpetual, worldwide license (with the right to sublicense) to make, have
made, copy, modify, make derivative works of, use, sell and otherwise distribute such Prior Invention as part of or in connection with such product, process or machine. 
 (c) Employee agrees to execute documents reasonable or necessary to vest all right, title, and interest in and to any Work Product, including, but not limited to, patents, patent applications and trademark, and
copyright filings. Employee shall maintain backup procedures during his/her employment with the Company to ensure that no data, documentation, program, text, specifications, notes, texts, drawings or other information prepared by Employee on behalf
of Company or any client are lost or destroyed. If the Company is unable, after reasonable effort, to secure Employee’s signature on any application for patent, copyright, trademark or other analogous protection or other documents regarding any
legal protection relating to Work Product, for any reason whatsoever, Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as his/her agent and attorney-in-fact, to act 

  

 6 

 
for and in his/her behalf and stead to execute and file any such application or applications or other documents and to do all other lawfully permitted acts
to further the prosecution and issuance of patent, copyright or trademark registrations or any other legal protection thereon with the same legal force and effect as if executed by Employee. 
 (d) This provision shall not apply to an invention that Employee developed entirely on his or her own time without using the Company’s equipment,
supplies, facilities, or trade secret information except for those inventions that either: (i) relate at the time of conception or reduction to practice of the invention to the Company’s business, or actual or demonstrably anticipated
research or development of the Company; (ii) result from any work performed by Employee for the Company or any client; or (iii) result from Employee’s use of Company resources or Property. 
 8. Remedies: 
 (a) Employee
acknowledges that compliance with Sections 3, 4, 5, 6 and 7 hereof is necessary to protect the business and goodwill of the Company and that any breach of such Sections will irreparably and continually damage the Company in such a manner that
money damages will not be an adequate remedy. Consequently, Employee agrees that, in the event of any breach or threatened breach any of the covenants contained in Sections 3 through 7 hereof, the Company shall be entitled to a preliminary
and/or permanent injunction in order to prevent the continuation of such damage without having to prove actual damages. The Company may apply for such injunctive relief in any court of competent jurisdiction without the necessity of posting any bond
or other security. Nothing contained in this Agreement shall limit the Company’s right to any other remedies at law or in equity. 
 (b)
Employee agrees that if he/she violates any restrictive covenant in this Agreement (including Sections 3, 4 and 5) after his/her employment with die Company has terminated, the term of any such covenant shall be tolled during the period of any
such violation. 
 9. Waiver of Rights: If, in one or more instances, either party shall fail to insist that the other party perform
any of the terms of this Agreement, such failure shall not be construed as a waiver by such party of any past, present or future right granted under this Agreement but the obligations of both parties under this Agreement shall continue in full force
and effect. This Agreement may not be modified except by an instrument in writing signed by the parties hereto. 
 10. Applicability and
Assignability: The Company shall have the right to assign this Agreement, or any rights and obligations hereunder to its successors and assigns, and all covenants and agreements hereunder shall inure to the benefit of and be enforceable by said
successors or assigns. Employee may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Company. 
  

 7 

 11. Reimbursement: Employee hereby authorizes the Company at any time during or after the term of
his/her employment to withhold from any amounts otherwise owed to Employee (including, but not limited to, salary, bonus, commissions and expense reimbursements) to the fullest extent permitted by applicable law. 
 13. Survival: Sections 3-11, 13, 14 and 16 hereof shall survive any termination or expiration of this Agreement. 
 14. Severability: If any of the provisions of this Agreement shall be invalid or unenforceable, such invalidity or unenforceability shall not
invalidate or render unenforceable the remainder of this Agreement, but rather the remainder of this Agreement shall be construed as if not containing the particular invalid or unenforceable provision or provisions, and the rights and obligations of
the parties shall be enforced accordingly. Moreover, if one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such
provision or provisions shall be construed by the appropriate judicial body by limiting, revising or reducing it or them, so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear. Employee hereby
further agrees that the language of all parts of this Agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for or against any of the parties. 
 15. Choice of Law: The construction, interpretation and performance of this Agreement shall be governed and construed in accordance with the laws
of the state of New Jersey, without giving effect to New Jersey’s principles of conflicts of laws. Any claims or legal actions by one party against the other shall be commenced and maintained in any state or federal court located in
New Jersey, and Employee hereby submits to the jurisdiction and venue of any such court. 
 16. Headings: The various headings in
the Agreement are inserted for convenience only and shall have no effect on the interpretation of this Agreement or any part hereof. 
  

 8 

 17. Entire Agreement: This Agreement constitutes the entire Agreement between the parties hereto
with respect to the subject matter hereof and supersedes all prior understandings and agreements between the parties hereto relating to the subject matter hereof. Employee acknowledges that Employee is not entering into this Agreement in reliance
upon any statement or representation except as otherwise expressly set forth herein. 
 IN WITNESS WHEREOF, this Agreement has been duly
executed and delivered by the parties as of date first above written. 
  
  
  
  

									
	         EMPLOYEE
  
	 		 	 AEGERION PHARMACEUTICALS, INC.
  

					
		 	/S/    CHRISTINE PELLIZZARI        	 		 	By:	 	/S/    GERALD WISLER        
		 		 		 		 	
					
		 		 		 	Title:	 	President and CEO
		 		 		 		 	
					
	Date:	 	July 31, 2007	 		 	Date:	 	July 31, 2007

  

 9 

 Exhibit B 
  

	TO:	Gerald Wisler 

 Aegerion Pharmaceuticals, Inc. 

CenterPaine IV 
 1140 Route 22 East

 Suite 304 
 Bridgewater, NJ
08807 
  

	RE:	Acceptance of Employment 

 DATE: August 1, 2007 
 I represent that to the best of my understanding, I am under no common law or contractual obligation that would be an impediment to my employment with
Aegerion Pharmaceuticals, Inc. (the “Company”). I will not use or disclose any confidential, proprietary or trade secret information belonging to any former employer, in my employment with the Company. 
 I represent and warrant that I have not retained or copied any confidential, proprietary or trade secret information or property, in tangible or
electronic form, belonging to any former employer. 
 I agree that, if at any time during my employment with the Company, I am at risk of
using or disclosing any confidential, proprietary or trade secret information belonging to any former employer, I will immediately recuse myself from acting on the matter and advise the President of the Company, without revealing any protected
information, the nature of my conflict; provided, however, that I will not be required to recuse myself in the event such disclosure is required by law or regulation or as a result of a response to a valid order of a court or another governmental
body of the United States or any political subdivision thereof. 
 I understand that if any of the representations or warranties herein are
intentionally false, or if I violate any of the terms of this memorandum, that my employment will be terminated and that such conduct may result in the forfeiture of any and all stock incentives (vested and unvested) awarded or issued to me at the
sole discretion of the Company and its Board of Directors. 
  

			
	Signature of Employee:	 	 /s/ Christine Pellizzari

	Print Name of Employee:	 	Christine Pellizzari

 Date: August 1, 2007 

 Exhibit I 
 TERMINATION CERTIFICATION 
 This is to certify that I do not have in my possession, nor have I failed to
return, any devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment or reproductions of any of the aforementioned items, any Company Documentation and any
Confidential Information (as defined in the Business Protection Agreement signed by me (the “Agreement”) belonging to the Company. 
 I further certify that I have complied with all the terms of the Agreement, including the reporting of any inventions and original works of authorship, developments, concepts, improvements or trade secrets, whether or not patentable or
registrable, under copyright or similar laws, conceived or made by me (solely or jointly with others) covered by the Agreement. 
 I further
agree that, in compliance with the Agreement, I will preserve as confidential all Confidential Information, including, but not limited to, trade secrets, confidential knowledge, data or other proprietary information relating to products, processes,
know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship, customer lists, business plans, financial information or other subject matter pertaining to any business of the
Company or any of its employees, clients, consultants or licensees. 
 I further agree to comply with the restrictive covenant provisions set
forth in Sections 3, 4 and 5 of the Agreement, which survive the termination of my employment. 
  

			
	Signature of Employee:	 	  

	Print Name of Employee:	 	

 Date:             , 2007 

 Exhibit II 
 LIST OF PRIOR INVENTIONS 
 AND ORIGINAL WORKS OF AUTHORSHIP 
 EXCLUDED FROM SECTION 7 OF THE AGREEMENT 
  

									
	 Title
	  	 Date
	  	 Identifying Number or Brief
Description

  

			
	     X    
	 	No inventions or improvements
		
	              
	 	Additional Sheets Attached

  

			
	Signature of Employee:	 	 /s/ Christine Pellizzari

	Print Name of Employee:	 	Christine Pellizzari

 Date: August 1, 2007 

 Section C 
 Agreement to Pay Severance 

 AGREEMENT TO PAY SEVERANCE 
 This Agreement to Pay Severance (the “Agreement”) is entered into as of this 31st day of July 2007 by and between Aegerion Pharmaceuticals,
Inc. (the “Company”) and Christine Pellizzari (the “Executive”). 
 WHEREAS, Executive agrees to commence employment with
the Company as its General Counsel; and 
 WHEREAS, the Company desires to provide Executive certain assurances with respect to her
eligibility to receive severance upon the termination of her at-will employment under the terms and conditions provided herein; 
 NOW
THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the Company and Executive agree as follows: 
  

	1.	Eligibility for Severance Upon Termination By The Company Without Cause Or Resignation By Executive For Good Reason. 

 (a) If the Company terminates Executive’s at-will employment for any reason other than for Cause (as defined below) or Executive terminates her
employment for Good Reason (as defined below), the Company shall provide Executive with the following severance payments and continued health insurance benefits: 
 (i) The Company will pay Executive severance at the rate of her then current monthly base salary for the period of nine (9) months
following the date of termination (the “Severance Period”). 
 (ii) Should the Executive elect to continue her
health and dental insurance coverage following the date of termination in accordance with the provision of COBRA, the Company shall pay the same percentage of the monthly premium for such health and dental insurance coverage as the Company paid
immediately prior to the date of termination for the period beginning on the date of termination and ending on the earlier to occur of (A) the date on which Executive obtains coverage under another health and dental insurance plan, or
(B) the expiration of the Severance Period. Thereafter, Executive shall by fully responsible for all premium payments under COBRA. Executive agrees and represents that he will provide prompt written notice of the date on which he obtains
coverage under another health and dental insurance plan following the date of her termination. 
 For the avoidance of doubt, Executive shall not be eligible
to receive the severance payments and continued health benefits described in this Section in the event that (y) her employment is terminated by the Company for Cause (as defined below) or due to Executive’s death or disability at any time
after the execution of this Agreement, or (z) she resigns from employment for other than Good Reason. In other words, the severance payment and continued health benefits described in Section 1(a) only apply upon a termination of
Executive’s employment by the Company without Cause or a resignation by Executive for Good Reason, and the fulfillment 

 
of each of the conditions set forth in this Agreement. Furthermore, except as expressly set forth in Section 1(a), the Executive acknowledges that the
Company shall not have any further obligations to the Executive in the event of her termination, except such further obligations as may be imposed by law. 
 (b) The severance payments shall be paid in accordance with the Company’s normal payroll practice and shall be subject to all applicable federal, state and local payroll and withholding taxes. 
 (c) If at the time of Executive’s termination of employment, she is considered a “specified employee” within the meaning of
Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”), and if any payment that Executive becomes entitled to receive under this Agreement is considered deferred compensation subject to interest and
additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, then no such payment shall be payable prior to the date that is the earliest of (i) six months and
one day after Executive’s date of termination, (ii) Executive’s death, or (iii) such other date as will cause such payment not to be subject to such interest and additional tax, and the initial payment shall include a catch-up
amount covering amounts that would otherwise have been paid during the first six-month period but for the application of this clause (c). 
  

	2.	Conditions to Receipt of Severance Payments and Continued Health Benefits. 

 (a) Execution of a Release. The Company’s provision of severance and other benefits set forth in Section 1 is subject to, and conditioned upon, Executive’s prior execution of a release agreement
in a form and scope acceptable to the Company. 
 (b) Compliance with Contractual Obligations. In addition, the Company’s
obligation to provide the severance and other benefits set forth in Section 1 shall be subject to Executive’s full compliance with all of her obligations under the Business Protection Agreement by and between Executive and the Company. In
the event that the Executive violates any of her obligations thereunder, the Company’s obligation to pay, and Executive’s right to receive, the severance payments shall immediately terminate. 
  

	3.	Definitions: 

 (a) Cause. For purposes of
this Agreement, the term “Cause” shall mean a termination by the Company for one or more of the following reasons: (i) Executive’s intentional, willful or knowing failure or refusal to perform her duties (other than as a result
of physical or mental illness, accident or injury) that in the sole discretion of the Board, may have a material adverse effect on the Company or any other material breach of this Agreement by Executive; (ii) dishonesty, willful or gross
misconduct, or illegal conduct by Executive in connection with her employment with the Company, which in the Board’s reasonable judgment may result in damage to the business or reputation of the Company; (iii) Executive’s conviction
of, or plea of guilty or nolo contendere to, a charge of commission of a felony (exclusive of any felony relating to negligent operation of a motor vehicle); and (iv) a material breach by Executive of the Business Protection Agreement or any
other written agreement with the 

 
Company; provided, however, in the case of clauses (i) and (iv) above, the Company shall be required to give Executive fifteen (15) calendar
days prior written notice of its intention to terminate Executive for Cause and Executive shall have the opportunity during such fifteen (15) days period to cure such event if such event is capable of being cured; provided, further, that in the
event that Executive terminates her employment with the Company during such fifteen (15) day period for any reason, such termination shall be considered a termination for Cause. 
 (b) Good Reason. For purposes of this Agreement, the term “Good Reason” shall mean a termination by Executive for one or more of the
following reasons: (i) Executive shall no longer serve in the capacity as the Company’s General Counsel, (ii) any reduction of Executive’s initial annual base salary of $225,000, other than pursuant to an across-the-board
reduction in the compensation of all senior management of the Company, provided that such reduction is proportionately equal among all such members of senior management, and (iii) a change without Executive’s consent in the principal
location of Executive’s office to an office that is more than fifty (50) miles form the Company’s proposed initial principal office location in the Bridgewater, New Jersey area, such consent not to be unreasonably withheld; provided
that, with respect to each of the reasons set forth above, Executive provides the Company with (y) written notice of her intention to terminate her employment for Good Reason within thirty (30) days after the occurrence of the event that
Executive believes would constitute Good Reason and (z) provides the Company with a period of at least fourteen (14) calendar days following receipt of such notice from Executive in which to cure the event giving rise to such Good Reason
termination. 
  

	4.	General Provisions. 

 (a) This Agreement shall be
governed by and construed in accordance with the laws of the State of New Jersey without giving effect to any choice or conflict of law provision or rule. This Agreement and its terms may not be waived, changed, discharged or terminated orally or by
any course of dealing between the parties, but only by an instrument in writing signed by the party against whom any waiver, change, discharge or termination is sought. 
 (b) This Agreement sets forth the complete and sole agreement between the parties with respect to Executive’s eligibility to receive severance payments and supersedes all prior agreements, understandings and
arrangements, whether written or oral, between Executive and the Company. 
 (c) Executive acknowledges that this Agreement is a not a
promise or guarantee of continued employment with the Company. Executive’s employment is, and will continue to be, on an at-will basis, which means that either Executive or the Company may terminate the employment relationship at any time, for
any or no reason, with or without cause. The terms above do not create any contractual rights to employment other than at-will and relate only to the Company’s obligation to pay Executive severance and other benefits upon the termination of
Executive’s employment in certain circumstances as described above. 
 (d) Executive does not have the right to assign or delegate her
rights hereunder to any other person or entity. The Company has the right to assign this Agreement and this Agreement shall inure to the benefit of, and be binding upon, the successors and assigns of the Company. 

 IN WITNESS WHEREOF, the Company and Executive have executed this Severance Agreement as of the date first
above written. 
  

							
	Aegerion Pharmaceuticals, Inc.	 	 	 	 
			
	 /s/ Gerald Wisler
	 		 	Date: August 1, 2007
	By:	 	Gerald Wisler	 		 	
	Title:	 	President and CEO	 		 	
			
	Christine Pellizzari	 		 	
			
	 /s/ Christine Pellizzari
	 		 	Date: August 1, 2007

 Amendment to Severance Agreement 
 This FIRST AMENDMENT TO SEVERANCE AGREEMENT dated as of November 15, 2007 is between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
and Christine Pellizzari (the “Executive”). 
 WHEREAS, the Executive is currently employed as a senior executive of the Company and in connection
with such employment is party to an Agreement to Pay Severance, dated July 31, 2007 (the “Agreement”); 
 WHEREAS, the Agreement contains certain
severance provisions in respect of the Executive; and 
 WHEREAS, the parties hereto consider it appropriate that the terms of the Executive’s severance
agreement with the Company be amended to prevent adverse tax treatment of severance payments to the Executive upon termination, and that such amendment be reflect in the terms set forth in the Agreement. 
 NOW, THEREFORE, the Company and the Executive agree to the following amendment to the terms of the Agreement. 
  

	1.	Definitions. Capitalized terms used in this Amendment and not otherwise defined herein shall have the meaning given to such terms in the Agreement. 

  

	2.	Section 1(c) of the Agreement is amended by adding “within 21 days following delivery of the release agreement to the Executive” before the period at the end of the first
and only sentence in the section. 

  

	3.	Scope of Amendment. Except as expressly set forth in this Amendment, the Agreement remains in effect without modification. 

  

	4.	Counterparts. This Amendment may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by different parties hereto in separate
counterparts, each of which when executed shall be deemed to be an original but all of which when taken together shall constitute one and the same agreement. 

 IN WITNESS WHEREOF, the Executive and the Company have executed this Amendment as of the date set forth above. 
  

					
	EXECUTIVE	 		 	AEGERION PHARMACEUTICALS, INC.
			
	/s/    Christine Pellizzari	 		 	/s/    William H. Lewis
	Name: Christine Pellizzari	 		 	 By: William H. Lewis
 Title: Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]